Thymosin alpha-1
Human research — investigational use
Research-only / investigational — not FDA approved
Investigational; no FDA-approved drug label is established for this entry. Source: FDA: safety concerns for nominated peptide substances
What it is
An immune-modulating peptide studied as an investigational treatment. Source: Randomized human trial: thymosin alpha-1 in sepsis
What it has been studied for
A randomized sepsis trial found no clear mortality benefit. This is not evidence for routine wellness use. Source: Randomized human trial: thymosin alpha-1 in sepsis
Mechanism
Investigated for modulation of immune responses in severe infection. Source: Randomized human trial: thymosin alpha-1 in sepsis
Documented dosing
No applicable general-use human dose range, frequency or cycle is documented here. Numbers from other routes, formulations or conditions are not interchangeable.
Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
FDA identifies unresolved safety concerns for this substance. Source: FDA: safety concerns for nominated peptide substances
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.
Sources
- Randomized human trial: thymosin alpha-1 in sepsis · Research publication
- FDA: safety concerns for nominated peptide substances · Clinical / regulatory reference